31 October 2019
Attention Deficit Hyperactivity Disorder Market Forecast 2020-2030: Forecasts and Analysis Drug Type (Stimulant, Non-stimulant), By Demographic, By Distribution Channel (Hospital & Retail Pharmacy) and Geography, with Profiles of Leading Companies, with Profiles of Leading Companies report provides impartial Attention Deficit Hyperactivity Disorder sector analysis.
According to the report published by Visiongain, the Attention Deficit Hyperactivity Disorder market market is projected at USD 17.7 billion in 2020 and is predicted to be 6.4 times CAGR over the 2020-2030 prediction. The industry is probable to be driven by product releases around the globe, acceptance of fresh drugs and enhanced research and development operations.
Attention Deficit Hyperactivity Disorder Market is witnessing Growth due to factors such as
The worldwide expenditure on ADHD drugs shifted from use to expenditure by 2003 was US$ 2.4 billion, indicating a nine-fold rise since 1993. Expenditure rose rapidly from 1993 to 2000, but the annual growth pace rose steeper to 40.9 points after 2000. This acceleration was mainly motivated by the U.S. industry, where new drugs were accessible, mainly longer-acting formulations. The U.S. dominates worldwide expenditure on ADHD medicines, accounting for about 92-95 percent of annual expenditure, with a development pace of 22.6 percent per year. Other nations reported a development level of expenditure mildly faster than the United States— about 21.0 percent per year. A country-by-country analysis reveals that spending increases were much more pronounced in developed countries.
During the study period, the use of ADHD drugs improved by 274 times. Global quantity rose rapidly from 1993 to 2000 (13.2 percent per year); development accelerated to 16.8 percent per year from 2000 to 2003. Global business percentage in the U.S. decreased from 86.8% in 1993 to 83.1% in 2003. A more thorough assessment shows significant country-by-country variability. Low-use nations showed development levels as large as 46% per year, while moderate-use nations showed development levels of approximately 20% per year. The U.S. market share should proceed to drop if these levels persist.
Attention-deficit-hyperactivity disorder (ADHD) impacts more than 40 million individuals across main pharmaceutical industries, kids, adolescents and adults. Key objectives for both pediatric and adult ADHD therapy include managing the core characteristics of inattention and/or hyperactivity / impulsivity of the disorder and enhancing the general workings and standard of lives of clients. Psychostimulants are the predominant category of drugs approved for pediatric and adolescent ADHD, although there are no stimulant therapies that function as alternatives or later choices. However, shortcomings in current therapies constitute prospective regions for differentiating from rivals for evolving therapies. Additionally, adult ADHD identification and diagnosis continues to develop, especially in the United States, but this population remains under detection and under-treatment, depicting a significant market opportunity.
Shift in Trends
Increased consciousness among the general population and authorities about mental health is anticipated to boost the industry for ADHD. Increasing numbers of individuals suffering from a variety of mental health disorders, including vision deficit / hyperactivity disease, have attracted government scrutiny around the globe, requiring them to adopt the needed measures to tackle this situation. The United States in 2016 For the next four years, the Department of Health & Human Services has granted up to USD 54 million to the Administration of Substance Abuse and Mental Health Services (SAMHSA) to tackle the requirements of people with severe social illness.
Similarly, in 2016, NHS England established a five-year mental health plan. The state has dedicated to applying this scheme by 2020–2021 with an investment of USD 1.27 billion. Therefore, public assistance is expected to increase the industry along with increasing consciousness among different sides. It is also anticipated that industry participants ' approval and marketing of fresh drugs will serve a vital part in promoting market growth over the coming years. For example, Shire launched FDA-approved MYDAYIS in August 2017 to treat age 13 and older ADHD patients.
In 2019, the stimulant section represented the biggest proportion in the ADHD industry and is anticipated to keep its dominance over the forecast period. This can be ascribed to elevated supply for these medicines owing to their efficacy in managing attention-deficit / hyperactivity disease diseases, continuing clinical studies, and public aid for stimulant use in psychiatric wellness disease therapyTris Pharma, Inc. announced in April 2016 the release of its FDA-approved liquid ADHD drug Dyanavel XR (amphetamine), which is used to cure clients over six years of era.
Due to their long-lasting impact relative to stimulants, non-stimulants are anticipated to show the highest development pace during the forecast period. Also a main element in boosting section development is the reality that these drugs do not pose any danger of substance abuse. In addition, a growing amount of market players have invested in the growth of attention-deficit / hyperactivity disease non-stimulant medicines, which drives the sector.
The industry was segmented into hospital and retail pharmacies based on the distribution channel of ADHD drugs. The highest market share was compensated for by retail pharmacy in 2018. The sector has been motivated by increased amount of prescriptions and increased customer support projects by retail pharmacies. Due to the long complexity of the disease therapy, ADHD nurses are less numerous than clients in homecare environments. Patients tend to buy drugs from retail pharmacies rather than clinics, so it is anticipated that the sector will maintain its advantage over the forecast period. The segment is also anticipated to register the highest CAGR of 6.6% from 2020 to 2030.
The general likelihood of Phase I ADHD property authorization is 12.9%, and the median likelihood of Phase III medication developments is 78.6%. Drugs, in the general psychiatry room, lasted an estimate of 8.9 years from Phase I to authorization opposed to 8.8 years. During 2014–19, there were 21 marketing and procurement agreements concerning ADHD medicines. The biggest deal was the acquisition by Impax Laboratories in 2016 of certain assets related to generic products from Teva and Allergan for $586 m.
The allocation of clinical studies through Phase I–IV shows that the bulk of ADHD studies were in the early design stages, with 54% in Phase III–IV and 46% in Phase I –II. The US has a significant increase in the amount of clinical trials of ADHD worldwide. Germany drives the EU's biggest economies, while Japan has Asia's top place. Completed studies dominate clinical test operation in the ADHD room. With 157 studies, Takeda has the largest amount of clinical trials finished for ADHD. Takeda brings the sector promoters, led by Eli Lilly and Johnson & Johnson, with the largest amount of clinical studies for ADHD.
Regional Market Analysis
North America dominated the worldwide industry and in 2018 represented more than 68.0 percent of the overall industry. This can be ascribed to the big quantity of annual drug prescriptions, improving brand releases, and enhancing player cooperation to improve market penetration and product development. Shire introduced a fresh prescription drug MYDAYIS (Adderall's recent version) in the U.S. for clients over 13 years of era with ADHD in August 2017. Atomoxetine capsule was introduced in October 2018 by Dr. Reddy's Laboratories to manage attention deficit / hyperactivity disease in the U.S. The marketing of products is therefore anticipated to increase the industry in North America. Due to increased knowledge of mental health, increased incidence of attention deficit / hyperactivity disease, elevated consumption of additives and preservatives, and improved publicity for the therapy of the disease, Europe is anticipated to develop at the highest pace during the forecast period.
Competition in the market
Dopamine, dopamine reuptake, norepinephrine (noradrenaline), norepinephrine (noradrenaline) reuptake / transporter and alpha-2 adrenergic cell are approved drugs in the ADHD room. The vast bulk of therapies authorized are given through the oral route. Phase III is the biggest percentage of industry-sponsored ADHD drugs in effective clinical development. Mid-to-late-stage production therapies for ADHD concentrate on a broad range of goals. Most mid-to-late-stage pipeline drugs are administered through the oral route, with only one drug being tried in intramuscular and subcutaneous formulations as well. Top-line Phase III trial findings, key efficacy research outcomes, anticipated patent expiration, and a conference with the FDA include the upcoming high-impact drug occurrences in the ADHD room.
It seems that the industry is extremely divided. Several firms, including Johnson and Johnson Services Inc. and NEOS Therapeutics Inc., are present, making the negotiating atmosphere quite intense. Factors such as rising ADHD incidence among kids and growing public aid will provide significant development possibilities for manufacturing drugs for attention deficit hyperactivity disorder. Amneal Pharmaceuticals Inc. and Takeda Pharmaceutical Co., Eli Lilly and Co. Ltd. are some of this report's significant businesses.
Key players in the market include Eli Lily & Company; Pfizer; Johnson & Johnson Services, LLC; Lupin; Shire; Mallinckrodt; Prude Pharma L.P.; and NEOS Therapeutics Inc. Effective and economical product development and geographic extension are some of the key approaches that market players have embraced to stay competitive.
For example, Pfizer received the U.S. in December 2015. Quillichew ER, a chewable tablet for ADHD therapy in nurses 6 years and older, is approved by FDA. This is available in formulations of 20 mg, 30 mg, and 40 mg. In addition, Lupin introduced a proprietary variant of Kapvay in the U.S. in February 2018, expanding its item range for attention-deficit / hyperactivity disease therapy
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The 431-page report provides clear detailed insight into the generic drugs market. Discover the key drivers and challenges affecting the market.
03 July 2020
Where is the Clinical Workflow Solutions market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2030, assessing data, trends, opportunities and business prospects there.
03 July 2020
With the growing burden of rare diseases around the world, there has been a rise and advancement in the therapy development of these types of diseases. While the fact remains that over 90% of these diseases lack approval for treatment and the total number of terminal rare diseases to receive the first treatment every year remains low.
01 July 2020
The market growth is attributed to the growing adoption of big data and AI in data management and monitoring of clinical information in health care.